Table 2.

Anticancer effects of EGCG based on animal studies.

Cancers	Animal models	EGCG treatments	Potential molecular mechanisms
Endometrial cancer	Transgenic luciferase-expressing mice (CMV-Luc)	EGCG and Pro-(EGCG octaacetate) 50 mg/kg	Inhibits tumor growth and angiogenesis [31]
	Female Syrian golden hamsters	65 mg/kg	Inhibits VEGF expression [61]
Breast cancer	Female C57BL/6 mice	50-100 mg/kg	Inhibits tumor VEGF expression [44]
	C57BL/6 aged (62-64 weeks old) and young (8 weeks old) mice	300 μg/30 μl DMSO	Inhibits DNA methyltransferase 2 (DNMT2) methylation activity [62]
Ovarian cancer	Female BALB/c nude mice	50 mg/kg	Inhibits tumor growth by regulating the PTEN/AKT/mTOR pathway [59]
	Female athymic (nu+/nu+) mice	12.4 g/L	Inhibition of tumor growth by the reduction of ETAR and ET-1 expression [60]

Abbreviations: VEGF, vascular endothelial growth factor; PTEN, phosphatase and tensin homolog; AKT, protein kinase B; mTOR, mammalian target of rapamycin; ETAR, selective receptor ETA; ET-1, the endothelin-1.